[1]姜海伟,胡晴,鄢艳红,等.免疫抑制剂对26例周围神经系统副肿瘤综合征的动态作用分析[J].卒中与神经疾病杂志,2017,24(05):439-443.[doi:10.3969/j.issn.1007-0478.2017.05.014]
　Jiang Haiwei,Hu Qing,Yan Yanhong,et al.The dynamic effects on immunosuppressive therapy to 26 cases of paraneoplastic peripheral nerve disease[J].Stroke and Nervous Diseases,2017,24(05):439-443.[doi:10.3969/j.issn.1007-0478.2017.05.014]
点击复制

免疫抑制剂对26例周围神经系统副肿瘤综合征的动态作用分析()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第24卷
期数:
2017年05期
页码:
439-443
栏目:
论 著
出版日期:
2017-10-26

文章信息/Info

Title:
The dynamic effects on immunosuppressive therapy to 26 cases of paraneoplastic peripheral nerve disease
文章编号:
1007-0478(2017)05-0439-05
作者:
姜海伟; 胡晴; 鄢艳红; 高畅; 曹梦莹; 葛林通
430033 武汉,湖北省第三人民医院神经内科
Author(s):
Jiang Haiwei; Hu Qing; Yan Yanhong; et; al.
Depurtment of Neurology,Third People's Hospital of Hubei Province,Wuhan 430033
关键词:
免疫抑制剂 综合征周围神经系统 相关性抗体 神经症状 动态作用
Keywords:
Immunosuppressive therapy Paraneoplastic peripheral nerve disease Related antibody Clinical neurological symptom Dynamic effects
分类号:
R739.4
DOI:
10.3969/j.issn.1007-0478.2017.05.014
摘要:
目的 探讨免疫抑制治疗对副肿瘤性周围神经疾病相关抗体定量与临床症状评分的动态影响。方法 对26例周围神经系统副肿瘤综合征患者进行规范化的免疫抑制剂治疗,在治疗前及治疗开始后1、4周、治疗结束后1周,治疗结束后3月五个时间点分别对患者血清抗-Hu抗体、抗-Yo抗体、 抗-Ri抗体进行定量检测,同时采用神经症状评分(NSS)、神经残疾评分(NDS)、改良神经功能(mRS)评分评估患者临床症状,并与抗体变化率进行相关性分析。结果 抗-Hu抗体(F=7.634,P=0.00 )、抗-Yo抗体(F=6.21,P=0.00)、 抗-Ri抗体(F=3.80,P=0.02 )定量总体变化均具有明显差异; 与治疗前比较,抗HU抗体在治疗开始1周后下降(t=3.70,P=0.01 ),但治疗结束后3月与治疗前比较无明显差异(t=1.00,P=0.33); mRS、NDS、NSS评分均在治疗后1周下降(mRS:t=2.37,P=0.03; NDS:t=2.58,P=0.02; NSS:t=3.39,P=0.00),但mRS评分(F=1.84,P=0.15 )评分总体变化无明显差异,NDS(F=3.27, P=0.02 )及NSS评分(F=4.89,P=0.01 )总体变化有明显差异,NDS评分治疗结束后1周仍明显下降(t=2.22,P=0.04)。治疗前相关抗体的定量与神经症状评分无明显关系(P>0.05),治疗开始后1周mRS及NSS评分的变化率与抗RI抗体的变化率呈正相关(mRS:r=0.46,P=0.02; NSS:r=0.40,P=0.04),而治疗开始后4周mRS评分的变化率与抗RI抗体的变化率(r=0.45,P=0.02)也呈正相关,其他抗体的变化与治疗开始后神经功能评分变化均无明显关系(P>0.05),而治疗结束后1周及治疗结束后3月抗体的变化与神经功能评分的变化均无明显关系(P>0.05)。结论 免疫抑制剂对系统副肿瘤周围神经综合征患者的抗体定量滴度及NDS、NSS症状评分方面具有一定的临床作用,与治疗结束后的长期作用无明显关系。
Abstract:
ObjectiveTo investigate the dynamic effect of the immunosuppressant on both paraneoplastic peripheral nerve disease related antibody titer and clinical symptom scores.Methods 26 cases of paraneoplastic peripheral nerve disease were received standardized immunosuppressant treatment,The serum antibodies of anti -Hu,anti -Yo and anti -Ri were quantitatively detected by ELISA method before treatment,one week during treatment,four weeks during treatment,one week after treatment and three months after treatment respectively.At the same time,the clinical symptoms were astimated with the Neurological Symptom Scale(NSS),Neurological Disability Scale(NDS),Modified Rankin Scale(mRS).Then to analysis correlation between the antibody titers and clinical symptoms on the change rate with the time of treatment.Results The overall changes on quantitative titer include of anti -Hu(F=7.634,P=0.00),anti -Yo(F=6.21,P=0.00),and anti -Ri(F=3.80,P=0.02)were statistically significant.Compared with before treatment,One weeks during the treatment,titer of anti Hu began to decline(t=3.70,P=0.01),but three months after treatment titer changes were not statistically significant compared with before treatment(t=1.00,P=0.33).Clinical symptom assessment: mRS,NDS,NSS in one weeks during treatment were decreased significantly(mRS:t=2.37,P=0.03; NDS:t=2.58,P=0.02; NSS:t=3.39,P=0.00)but the overall change on mRS(F=1.84,P=0.15)was not statistically significant,the overall change on NDS(F=3.27,P=0.02)and NSS(F=4.89,P=0.01)was statistically significant,NDS,NSS in four weeks after treatment were decreased significantly compared with before treatment(t=2.22,P=0.04).Before treatment,There was no significant correlation between the titer of antibody and neurological symptom score(P>0.05).In one weeks during treatment,the change rates of mRS and NSS were correlated with the rate of anti -RI(mRS:r=0.46,P=0.02; NSS:r=0.40,P=0.04).In four weeks during treatment,the change rate of mRS was correlated with the rate of anti -RI(r=0.45,P=0.02).There was no significant correlation in change rate beteween other antibodies and neurological symptom score during treatment(P>0.05).There was no significant correlation in change rate beteween all antibodies and neurological symptom score after treatment(P>0.05).Conclusion Immunosuppressive therapy could effectively inhibit the titer of antibody and properly relieve clinical symptoms associated with paraneoplastic peripheral nerve disease.It's long-term effects after treatment was no significant correlation.

参考文献/References:

[1] 吴江,贾建平,崔丽英.神经病学[M].北京:人民卫生出版社,2005:419-423.
[2] Dyck PJ.Detection,characterization,and staging of polyneuropathy: assessed in diabetics[J].Muscle Nerve,1988,11(1):21-32.
[3] 吕少萍.神经系统副肿瘤综合征的生物标志物检测[D].济南:山东大学,2013:25-32.
[4] 姜海伟,胡晴,鄢艳红,等.免疫抑制治疗对36例神经系统副肿瘤综合征相关抗体定量的动态影响[J].卒中与神经疾病,2016,23(2):80-83.
[5] Shams'ili S.Janet de beukelaar,Jan willem gratama,e t al.an uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes[J].J Neurol,2006,253(1):16-20.
[6] De Jongste AH,Van Gelder T,Bromberg JE,et al.A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes[J].Neuro Oncol,2015,17(1):145-150.
[7] Orange D,Frank M,Tian S,et al.Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens[J].Arch Neurol,2012,69(9):1132-1140.
[8] Paul NL,Kleinig TJ.Therapy of paraneoplastic disorders of the CNS[J].Expert Rev Neurother,2015,15(2):187-193.
[9] 刘琳琳,刘冉.神经系统副肿瘤综合征抗体[J].国际神经病学神经外科学杂志,2012,39(1):98-101.
[10] Greenlee JE,Clawson SA,Hill KE,et al.Neuronal uptake of anti-Hu antibody,but not anti-Ri antibody,leads to cell death in brain slice cultures[J].J Neuroinflammation,2014,11(1):160.
[11] Nicola LMP,Timothy JK.Therapy of paraneoplastic disorders of the CNS[J].Neurother,2015,15(2):187-193.
[12] Giometto B,Vitaliani R,Lindeck-Pozza E,et al.Treatment for paraneoplastic neuropathies[J].Cochrane Database Syst Rev,2012,12: CD007625.DOI:10.1002/14651858.12.Dec.2012.
[13] Honnorat J.Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome[J].Clin Exp Immunol,2014,178(Suppl 1):127-129.

备注/Memo

备注/Memo:
基金项目:2015年—2016年湖北省卫生计生指导性项目(项目编号为WJ2015052)
更新日期/Last Update: 2017-10-20